An Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Ethinyl Estradiol and Levonorgestrel in Healthy Female Participants of Non-Child-Bearing Potential
Latest Information Update: 14 Feb 2023
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary) ; Zibotentan (Primary)
- Indications Liver cirrhosis; Liver failure; Renal failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 08 Feb 2023 Status changed from active, no longer recruiting to completed.
- 12 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2022 Planned number of patients changed from 42 to 24.